Our group identified CREBBP/EP300 mutations as predictors of poor outcomes in patients with newly diagnosed DLBCL treated with R-CHOP, while SOCS1 mutations were associated with better prognoses [36]. This evidence concerns the gene EP300 and diffuse large B-cell lymphoma.